Synthesis and Toxicological Evaluation of N‐Nitroso Vildagliptin Amide Impurity in BALB 3T3 Clone Cells
- 12 November 2025
- journal article
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (5) , 1654-1666
Abstract
Nitrosamine impurities in pharmaceuticals have become a significant regulatory concern because of their established carcinogenic and genotoxic potential. N‐nitroso vildagliptin amide impurity (NNVI), associated with the antidiabetic drug vildagliptin, raises potential safety concerns, yet its biological toxicity remains inadequately explored. To address this gap in our study, we synthesized and characterized NNVI and evaluated its cytotoxic, oxidative, and genotoxic effects using BALB 3T3 cell lines, within the context of the US FDA's acceptable daily intake (ADI) limit for NNVI. NNVI was synthesized under mild acidic conditions via nitrosation of the vildagliptin amide intermediate and confirmed structurally using NMR, IR, and mass spectrometry. BALB 3T3 cells were treated with NNVI at concentrations ranging from 5 to 125 ppm. Cytotoxicity was assessed with the MTT assay, whereas oxidative stress was measured via levels of superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), nitric oxide synthases (iNOS), reduced glutathione (GSH), and Nrf2. Genotoxicity was determined through the alkaline comet assay. The results showed a dose‐dependent decrease in cell viability, with significant cytotoxicity observed at concentrations ≥ 50 ppm. Oxidative stress markers indicated adaptive antioxidant responses at lower concentrations (5–25 ppm), but higher concentrations caused oxidative imbalance, antioxidant depletion, and increased lipid peroxidation. Genotoxic effects were evident at 100 ppm, with increased DNA tail intensity. These findings confirm that NNVI presents a toxicological risk at concentrations above regulatory limits. The study underscores the importance of strict impurity control in pharmaceutical formulations and contributes to the wider effort of ensuring drug safety by limiting nitrosamine exposure to acceptable thresholds.Keywords
This publication has 16 references indexed in Scilit:
- Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakesRegulatory Toxicology and Pharmacology, 2024
- Forced Degradation Products of Olmesartan Medoxomil and their In Vitro Genotoxicity Assessment by Comet Assay using HEK CellsChemistrySelect, 2024
- In vitro toxicity of fine and coarse particulate matter on the skin, ocular and lung microphysiological cell-culture systemsToxicology, 2023
- Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC‐MSJournal of Separation Science, 2021
- Critical Analysis of Drug Product Recalls due to Nitrosamine ImpuritiesJournal of Medicinal Chemistry, 2021
- Glutathione synthesisBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Reaction of Peroxynitrite with Mn-Superoxide DismutaseJournal of Biological Chemistry, 2001
- An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response ElementsBiochemical and Biophysical Research Communications, 1997
- Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Catalase1965